First Analysis Thinks Adicet Bio’s Stock is Going to Recover

By Austin Angelo

First Analysis analyst First Analysis initiated coverage with a Buy rating on Adicet Bio (ACETResearch Report) on March 31. The company’s shares closed last Friday at $13.52, close to its 52-week low of $6.02.

Adicet Bio has an analyst consensus of Moderate Buy, with a price target consensus of $25.00, which is a 77.7% upside from current levels. In a report issued on February 20, Wedbush also initiated coverage with a Buy rating on the stock with a price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.